Global Retirement Partners LLC Acquires New Position in Natera, Inc. $NTRA

Key Points

• Global Retirement Partners acquired 5,635 Natera shares worth approximately $1.53 million in the second quarter. Institutional investors collectively own 99.90% of Natera’s stock.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst estimates, while adjusted EPS of negative $0.47 slightly beat expectations.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $319.38 price target. Natera shares opened at $314.18, near their 52-week high of $326.03.

Global Retirement Partners LLC bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 5,635 shares of the medical research company's stock, valued at approximately $1,530,000.

Several other hedge funds and other institutional investors have also bought and sold shares of NTRA. Integrated Wealth Concepts LLC raised its stake in shares of Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock worth $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC boosted its stake in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock valued at $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock valued at $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera during the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera during the 2nd quarter valued at $558,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Stock Up 1.4%

NASDAQ:NTRA opened at $314.18 on Tuesday. The firm has a market capitalization of $45.29 billion, a P/E ratio of -231.01 and a beta of 1.51. The company has a fifty day moving average of $265.78 and a 200 day moving average of $226.82. Natera, Inc. has a 52 week low of $156.71 and a 52 week high of $326.03.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter last year, the firm earned ($0.74) EPS. The company's revenue was up 37.7% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -1.11 EPS for the current year.

Insider Activity

In other Natera news, insider John Fesko sold 295 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05. Following the completion of the transaction, the insider owned 183,774 shares of the company's stock, valued at $49,249,594.26. This represents a 0.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer directly owned 99,897 shares of the company's stock, valued at $26,611,561.83. The trade was a 2.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 181,045 shares of company stock valued at $41,330,968. Company insiders own 5.05% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on NTRA shares. Piper Sandler boosted their price target on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. The Goldman Sachs Group assumed coverage on Natera in a research note on Friday, June 5th. They set a "neutral" rating and a $245.00 price objective on the stock. Evercore reiterated an "outperform" rating and issued a $300.00 price objective on shares of Natera in a report on Monday, July 6th. Guggenheim boosted their target price on Natera from $290.00 to $360.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Finally, JPMorgan Chase & Co. increased their target price on Natera from $315.00 to $360.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source